A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician's Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)
Clinical Trial Grant
Awarded By
AstraZeneca AB
Start Date
November 19, 2024
End Date
June 23, 2029
Awarded By
AstraZeneca AB
Start Date
November 19, 2024
End Date
June 23, 2029